Providence Infusion Hospital Services (Providence Health and Services Washington), Tukwila, WA
Is Providence Infusion Hospital Services (Providence Health and Services Washington) registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels its entry 503B, with FDA’s note “Out of business”.
Does Providence Infusion Hospital Services (Providence Health and Services Washington) hold a Washington pharmacy license?
State board of pharmacy records for Washington are not checked: the Department of Health’s open dataset on data.wa.gov lists individual credentials but not pharmacy licenses, and its enforcement column has been removed for now; the department’s provider search is an interactive search, which this index does not use.
Has Providence Infusion Hospital Services (Providence Health and Services Washington) had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 2 FMD-145 letters (Sep 10, 2021 and Aug 16, 2022) for Providence Infusion Hospital Services (Providence Health and Services Washington). State board of pharmacy records for Washington are not checked: the Department of Health’s open dataset on data.wa.gov lists individual credentials but not pharmacy licenses, and its enforcement column has been removed for now; the department’s provider search is an interactive search, which this index does not use.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Providence Health and Services Washington; Providence Infusion Hospital Services
- Location
- Tukwila, WA
- Type as FDA labels it
- 503B
- FDA’s note
- Out of business
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 2
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Aug 16, 2022
- FDA Data Dashboard inspections
- 2 inspections: 2 VAI; 2 published Form 483s
- Form 483 text on this page
- 1 Form 483, 1 observation
- State board records
- Not checked
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Providence Health and Services Washington, (dba Providence Infusion Hospital Services), a 503B facility, with 4 dated actions.
| Document | |||
|---|---|---|---|
| Aug 16, 2022 | FMD-145 letter | FMD-145 Letter Issued 08/16/2022 | Not linked by FDA |
| Apr 13, 2022 | Form 483 | 483 Issued 04/13/2022 | FDA copy (archived) |
| Sep 10, 2021 | FMD-145 letter | FMD-145 Letter Issued 09/10/2021 | Not linked by FDA |
| Oct 5, 2020 | Form 483 | 483 Issued 10/05/2020 | fda.gov |
A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Providence Health and Services Washington, Tukwila, WA (FEI number 3014577316), matched to this page by exact name, city and state. It lists 2 inspections: 2 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Apr 13, 2022 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3014577316 | 1166993 |
| Oct 5, 2020 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3014577316 | 1130801 |
Form 483s FDA has published for this site
- Apr 13, 2022: Form 483 to Providence Health and Services Washington, published Nov 7, 2022. fda.gov
- Oct 5, 2020: Form 483 to Providence Health and Services Washington, published Dec 17, 2021. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483 for this site has 1 numbered observation in all. Each observation is quoted from the PDF as FDA numbered it. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Mar 15, 2022 to Apr 13, 2022: 1 observation
- Firm on the cover
- , Providence Health a nd S ervices W ashington Db a Pr ovidence In fusion Ho spital Ser vices 3333 S 120 th Pl Ste 100c, Tukwila, WA 98168- 5134
- FEI number
- 3014577316
- Establishment type on the cover
- Outsourcing F acility
- FDA district office on the cover
- Not read
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
The flow of components, drug product containers, closures and in-process materials through the building is not designed to prevent contamination.
Specifically,
On 03/17/2022, during the production of ceFAZolin 3 gra m per 30mL Syringe, Lo t: <Reda cted B4> a compounding technicia n used a <Redacted B4> cabin et to transfer the compounded sterile drug product from your ISO 7 classified Cleanroom <Redacted B4> to an unclassified Room <Redacted B4> during filling operations multiple times.
In addition, your firm management stated that the <Redacted B4> cabinet leading from the unclass ified Room <Redacted B4> to the ISO 7 classified Cleanroom <Redacted B4> was used to move i tems needed for the steri le drug production of ceFAZolin <Redacted B4> times from O1/01/2021 to 03/20/2022.For instance, your firm produced ceFAZolin 2g per 20mL Syringe, Lot: <Redacted B4> on 02/11/2022. During the production of this lot of ceFAZolin your management stated the <Redacted B4> cabinet was used to transfer items used in the sterile drug production.
Linked 483s whose text is not shown
- Oct 5, 2020: FDA document 154888: its numbered observations could not be read reliably from the PDF text.
State board of pharmacy records
State board of pharmacy records for Washington are not checked: the Department of Health’s open dataset on data.wa.gov lists individual credentials but not pharmacy licenses, and its enforcement column has been removed for now; the department’s provider search is an interactive search, which this index does not use.
This page restates FDA’s lists. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
Records last pulled Nov 15, 2026. Every entry links to the original public record.